Development
Dyne Therapeutics, Inc.
DYN
$10.47
$0.222.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.34% | -4.51% | 1.84% | -3.94% | -1.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.65% | 17.42% | 6.20% | 12.43% | 13.96% |
| Operating Income | -41.65% | -17.42% | -6.20% | -12.43% | -13.96% |
| Income Before Tax | -40.36% | -14.95% | -3.87% | -10.50% | -12.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.36% | -14.95% | -3.87% | -10.50% | -12.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.36% | -14.95% | -3.87% | -10.50% | -12.60% |
| EBIT | -41.65% | -17.42% | -6.20% | -12.43% | -13.96% |
| EBITDA | -42.07% | -17.55% | -6.16% | -12.28% | -13.66% |
| EPS Basic | -21.76% | -2.40% | 3.76% | -7.13% | -10.66% |
| Normalized Basic EPS | -21.76% | -2.41% | 3.76% | -7.16% | -10.66% |
| EPS Diluted | -21.76% | -2.40% | 3.76% | -7.13% | -10.66% |
| Normalized Diluted EPS | -21.76% | -2.41% | 3.76% | -7.16% | -10.66% |
| Average Basic Shares Outstanding | 14.80% | 11.36% | 7.10% | 3.37% | 2.13% |
| Average Diluted Shares Outstanding | 14.80% | 11.36% | 7.10% | 3.37% | 2.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |